Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

Maura N. Dickler; William Thomas Barry; Constance T. Cirrincione; Matthew James Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S. Rugo; Diana Lake; Olwen Mary Hahn; Bryan P. Schneider; Debu Tripathy; Eric P. Winer; Clifford A. Hudis

doi:10.1200/jco.2015.33.15_suppl.501

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.501 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 501-501 ◽

Cited By ~ 11

Author(s):

Maura N. Dickler ◽

William Thomas Barry ◽

Constance T. Cirrincione ◽

Matthew James Ellis ◽

Mary Ellen Moynahan ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy155 ◽

2018 ◽

Vol 29 (7) ◽

pp. 1541-1547 ◽

Cited By ~ 148

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

10.1158/1538-7445.sabcs14-ot2-1-06 ◽

2015 ◽

Cited By ~ 5

Author(s):

Roisin M Connolly ◽

Fengmin Zhao ◽

Kathy D Miller ◽

Amye J Tevaarwerk ◽

Lynne I Wagner ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz215 ◽

2019 ◽

Vol 30 (11) ◽

pp. 1842 ◽

Cited By ~ 6

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

npj Breast Cancer ◽

10.1038/s41523-017-0053-3 ◽

2018 ◽

Vol 4 (1) ◽

Cited By ~ 22

Author(s):

Sri Lakshmi Hyndavi Yeruva ◽

Fengmin Zhao ◽

Kathy D. Miller ◽

Amye J. Tevaarwerk ◽

Lynne I. Wagner ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

10.1158/1538-7445.sabcs15-ot2-01-04 ◽

2016 ◽

Author(s):

R Connolly ◽

F Zhao ◽

K Miller ◽

A Tevaarwerk ◽

L Wagner ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Research Group ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Download Full-text

Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy424.011 ◽

2018 ◽

Vol 29 ◽

pp. viii709 ◽

Cited By ~ 1

Author(s):

Z. Jiang ◽

W. Li ◽

X. Hu ◽

Q. Zhang ◽

T. Sun ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Histone Deacetylase ◽

Hdac Inhibitor ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Subtype Selective

Download Full-text

Definition of First-Line Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2015.66.0803 ◽

2016 ◽

Vol 34 (16) ◽

pp. 1959-1960 ◽

Cited By ~ 2

Author(s):

Tomás Reinert ◽

Carlos H. Barrios

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

First Line ◽

Hormone Receptor Positive ◽

Definition Of

Download Full-text

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

10.1158/1538-7445.sabcs17-gs2-05 ◽

2018 ◽

Cited By ~ 16

Author(s):

D Tripathy ◽

J Sohn ◽

S-A Im ◽

M Colleoni ◽

F Franke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Premenopausal Women ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Hormone Receptor Positive

Download Full-text

Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis

10.1158/1538-7445.sabcs18-p6-18-05 ◽

2019 ◽

Author(s):

D Tripathy ◽

G Hortobagyi ◽

A Chan ◽

S-A Im ◽

S Chia ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

First Line ◽

Efficacy Analysis ◽

Hormone Receptor Positive

Download Full-text

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06319-z ◽

2021 ◽

Author(s):

Mei-Yin C. Polley ◽

Maura N. Dickler ◽

Jason Sinnwell ◽

Kathleen Tenner ◽

Juan de la Haba ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

First Line ◽

Hormone Receptor Positive ◽

Disease Outcomes

Download Full-text